Trial Profile

DIVERGE-II

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Jan 2010

At a glance

  • Drugs Umirolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Registrational; Therapeutic Use
  • Acronyms DIVERGE-II
  • Sponsors Devax
  • Most Recent Events

    • 08 Jun 2009 New trial record.
    • 30 May 2009 The U.S. Food and Drug Administration has conditionally approved an Investigational Device Exemption the AXXESS Biolimus A9-eluting stent, allowing the company to initiate this pivotal trial in the USA; as reported by Devax in a media release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top